← ANALYST RATINGS · TIPRANKS
NervGen Pharma (NGEN): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $10.00, the highest $10.00, the lowest $10.00. The average is +528.9% from the last price of $1.59.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $1.50 | Sell | −5.7% | Downgrade | 15.10.26on TipRanks 10:05 | — | |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $2.00 → $1.50−25.0% | Hold | −5.7% | Reiterated | 07.10.26on TipRanks 16:05 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $2.00 → $1.50−25.0% | Hold | −5.7% | Upgrade | 07.10.26on TipRanks 16:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $2.00 → $1.50−25.0% | Hold | −5.7% | Reiterated | 07.10.26on TipRanks 07:08 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $2.00 → $1.50−25.0% | Sell | −5.7% | Reiterated | 02.10.26on TipRanks 06:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $2.00 → $1.50−25.0% | Hold | −5.7% | Upgrade | 02.10.26on TipRanks 06:05 | — | |
| Marc Goodman★★★★★★★★★★#365 · hits 56% · avg +19.2% | Leerink Partners | $10.00 | Buy | +528.9% | Reiterated | 01.10.26on TipRanks 13:55 | −8.0%next day +0.4% · 5 days −1.9% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 13.08.26on TipRanks Aug 17 05:54 | −0.7%next day −1.2% · 5 days +2.0% | ↗ |
| Ram Selvaraju★★★★★★★★★★#212 · hits 57% · avg +24.4% | H.C. Wainwright | $18.00 → $15.00−16.7% | Buy | +843.4% | Reiterated | 14.07.26on TipRanks 06:10 | −10.2%next day −3.3% · 5 days +2.8% | ↗ |
| Justin Keywood★★★★★★★★★★#7275 · hits 51% · avg +0.3% | Stifel Nicolaus | $6.00 | Buy | +277.4% | Reiterated | 21.05.26on TipRanks May 24 14:15 | −1.8%next day −43.9% · 5 days −45.6% | ↗ |
| Elemer Piros★★★★★★★★★★#12258 · hits 35% · avg −8.3% | Lucid Capital | $18.00 | Buy | +1,032.1% | Initiated | 15.04.26on TipRanks 06:15 | +0.4%next day −2.1% · 5 days −6.7% | ↗ |
| Andre Uddin★★★★★★★★★★#680 · hits 46% · avg +30.3% | Research Capital | $5.50 | Buy | +245.9% | Reiterated | 10.04.26on TipRanks 13:30 | −3.7%next day 0.0% · 5 days −4.0% | ↗ |
| Michael Okunewitch★★★★★★★★★★#11525 · hits 36% · avg −3.3% | Maxim Group | $10.00 → $12.00+20.0% | Buy | +654.7% | Assigned | 09.04.26on TipRanks Apr 8 15:25 | +2.7%next day +0.1% · 5 days −2.1% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering NervGen Pharma
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $12.50 at a price of $1.91 (+554.5%); now: $10.00 at $1.59 (+528.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 1 | 1 | 1 | 1 |
| Buy | 2 | 3 | 1 | 2 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 12.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.09 (from $-0.10 to $-0.08). Last quarter: $-0.27.
Best top-analyst consensus in the sector · Healthcare
About NervGen Pharma
- CEO: Harold Martin Punnett
- Employees: 11
- 2955 Virtual Way, Vancouver, BC, V5M 4X6, CA
- www.nervgen.com
NervGen Pharma Corp., along with its affiliated entities, is a pharmaceutical company dedicated to discovering, advancing, and commercializing innovative drug therapies for neurological conditions involving nerve damage. Its flagship investigational therapy, NVG-291, is currently undergoing Phase 1 clinical trials, targeting significant neurological disorders such as spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. NervGen has also secured an exclusive licensing agreement with Case Western Reserve University. This partnership enables the company to research, advance, and commercialize a proprietary technology holding considerable therapeutic promise for SCI and a range of other nerve-related ailments. Established in 2017, NervGen Pharma Corp. maintains its headquarters in Vancouver, Canada.
Data from the stock’s TipRanks forecast page, read 297 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗